<DOC>
	<DOCNO>NCT00612586</DOCNO>
	<brief_summary>This study evaluate addition enzastaurin 5-FU ( 5-fluorouracil ) /LV ( leucovorin ) plus bevacizumab maintenance best response obtain 6 cycle first-line therapy consist FOLFOX ( 5-FU/LV + oxaliplatin ) FOLFIRI ( 5-FU/LV + irinotecan ) , plus bevacizumab patient Metastatic Colorectal Cancer .</brief_summary>
	<brief_title>Phase 2 Study Enzastaurin With 5 FU/LV Plus Bevacizumab Maintenance Regimen Following First Line Therapy Metastatic Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologic diagnosis locally advance metastatic CRC curable . The histology type include adenocarcinoma , mucinous adenocarcinoma , signet ring , undifferentiated . Patients neuroendocrine carcinoma exclude . Received 6 cycle ( 3 month [ 12 week ] ) firstline therapy FOLFOX FOLFIRI , plus bevacizumab metastatic CRC . Patients receive least 5 cycle bevacizumab . Patients receive 6 cycle firstline therapy FOLFOX FOLFIRI , plus bevacizumab recurrent CRC relapse least 12 month completion adjuvant therapy also include . All standard FOLFOX ( FOLFIRI ) regimens give biweekly schedule permit ; however , 21day regimen allow . No 4 week may pass end firstline therapy ( , Day 14 Cycle 6 ) randomization . Documented evidence tumor response CR , PR , SD compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) . Confirmation response require . Are unable swallow tablet . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have know central nervous system metastasis . Are receive concurrent administration antitumor therapy . Patients significant heart , liver , kidney , psychiatric disease active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>